Chris Ryan on Muck Rack

Chris Ryan

Verified
New Jersey
As seen in: MJH Life Sciences, OncLive, MSN, NJ.com, The Star-Ledger, Health, Penn Live Patriot-News, SPIN, Lehigh Valley Live, Staten Island Advance, Syracuse.com, NewsBreak and
Managing Editor, @OncLive. Noted tall person. Recovering sports reporter. Past: @njdotcom. I know way too much about the Devils.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chris

Contact Chris, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL

|
By Riley Kandel, Chris Ryan , Kyle Doherty
| OncLive
First-line zanubrutinib (Brukinsa) monotherapy was associated with improved real-world efficacy compared with ibrutinib (Imbruvica) or acalabrutinib (Calquence) in older patients with chronic lymphocytic leukemia (CLL), according to data from a retrospective analysis using Medicare data, which was presented at the 2026 ASCO Annual Meeting.1 In adjusted Cox models, patients with CLL who were Medicare beneficiaries and received zanubrutinib (n = 3006) experienced a median time to treatment...
Open in Who Shared Issue with article?

Varegacestat Represents Potential SOC for Progressing Desmoid Tumors

|
By Chris Ryan , Riley Kandel, Kyle Doherty
| OncLive
Treatment with varegacestat (AL102) significantly improved progression-free survival (PFS) and objective response rate (ORR) vs placebo in patients with progressing desmoid tumors, according to data from the phase 3 RINGSIDE trial (NCT04871282) presented at the 2026 ASCO Annual Meeting.1 The trial met its primary end point, with varegacestat (n = 79) reducing the risk of disease progression or death by 84% vs placebo (n = 77; HR, 0.16; 95% CI, 0.07-0.38; P < .0001).
Open in Who Shared Issue with article?

First-Line Pemigatinib Drives PFS Benefit in FGFR2-Rearranged Cholangiocarcinoma

|
By Chris Ryan , Kyle Doherty
| OncLive
First-line pemigatinib (Pemazyre) significantly prolonged progression-free survival (PFS) compared with gemcitabine plus cisplatin in patients with unresectable, locally advanced, or metastatic cholangiocarcinoma harboring FGFR2 rearrangements, according to data from the phase 3 FIGHT-302 trial (NCT03656536) presented at the 2026 ASCO Annual Meeting.1 Findings demonstrated that pemigatinib (n = 83) yielded a median PFS of 8.34 months (95% CI, 6.51-12.22) vs 6.80 months (95% CI, 6.05-8.25)...
Open in Who Shared Issue with article?
See all 4,386 licensed articles (4,459 Total)

Actions

Share this page

Get in touch with Chris

Contact Chris, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified